Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Bupropion hydrochloride is effective in promoting long-term abstinence from smoking and may reduce risk for relapse through attenuation of withdrawal symptoms and craving. Bupropion is a weak dopamine reuptake inhibitor, and individual genetic variation in the dopamine D2 receptor has been associated with nicotine dependence in case-control studies. Thirty smokers were randomly assigned to bupropion or placebo and interviewed using the Minnesota Nicotine Withdrawal Scale on two occasions: prior to starting medication and after 14 days on bupropion or placebo. The individual symptoms of craving, irritability, and anxiety were significantly reduced in the bupropion group, whereas no withdrawal symptoms were diminished in the placebo group. Within the bupropion group, subgroup analyses with stratification by genotype demonstrated that craving, irritability, and anxiety were significantly attenuated only among subjects with DRD2-Taq1 A2/A2 genotypes. In the DRD2-Taq1 A1/A1 and A1/A2 groups, no significant reduction was seen in any individual symptom of the nicotine withdrawal syndrome. These data suggest that bupropion attenuates specific symptoms of the nicotine withdrawal syndrome and that this effect may be modified by genotype for the dopamine D2 receptor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fagerström, K.-O. (1978) · Addictive Behaviors · doi:10.1016/0306-4603(78)90024-2 · Cited by 2,221 · cited 1×
“Nicotine Dependence (FTND; Fagerström, 1978)”
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585
Allelic Association of Human Dopamine D2 Receptor Gene in Alcoholism
Blum, K. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03440150063027 · Cited by 1,055
First lapses to smoking: Within-subjects analysis of real-time reports.
Shiffman, S., Paty, J. A., Gnys, M., Kassel, J. A., & Hickcox, M. (1996) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.64.2.366 · Cited by 745
Cigarette smoking: implications for psychiatric illness
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.4.546 · Cited by 723
Noble, E. P. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810310066012 · Cited by 655
Reward deficiency syndrome: genetic aspects of behavioral disorders
Comings, D. E., & Blum, K. (2000) · Progress in Brain Research · doi:10.1016/s0079-6123(00)26022-6 · Cited by 621
Thompson, J., Thomas, N., Singleton, A., Piggot, M., Lloyd, S., Perry, E. K., Morris, C. M., Perry, R. H., Ferrier, I. N., & Court, J. A. (1997) · Pharmacogenetics · doi:10.1097/00008571-199712000-00006 · Cited by 553
Bupropion is a nicotinic antagonist
Slemmer, J. E., Martin, B. R., & Damaj, M. I. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38905-0 · Cited by 509
The D 2 Dopamine Receptor Gene as a Determinant of Reward Deficiency Syndrome
Blum, K., Sheridan, P. J., Wood, R. C., Braverman, E. R., Chen, T. J. H., phd, J. G. C., & Comings, D. E. (1996) · Journal of the Royal Society of Medicine · doi:10.1177/014107689608900711 · Cited by 443
Cited by
Antidepressants for smoking cessation
Hughes, J. R., Stead, L. F., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub3 · Cited by 567
Antidepressants for smoking cessation
Howes, S., Hartmann-Boyce, J., Livingstone-Banks, J., Hong, B., & Lindson, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub5 · Cited by 1,352
Antidepressants for smoking cessation
Hughes, J. R., Stead, L. F., Hartmann-Boyce, J., Cahill, K., & Lancaster, T. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub4 · Cited by 348
Interventions for preventing weight gain after smoking cessation
Farley, A. C., Hajek, P., Lycett, D., & Aveyard, P. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006219.pub3 · Cited by 334
Antidepressants for smoking cessation
Hajizadeh, A., Howes, S., Theodoulou, A., Klemperer, E., Hartmann-Boyce, J., Livingstone-Banks, J., & Lindson, N. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub6 · Cited by 84
Metadata
- Authors
- Murphy, M., Johnstone, E., Griffiths, S.-E., Walton, R., David, S., Niaura, R., Papandonatos, G., Shadel, W., Burkholder, G., Britt, D., Day, A., Stumpff, J., & Hutchison, K.
- Venue
- Nicotine & Tobacco Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-12-01
- Volume
- 5
- Issue
- 6
- Pages
- 935-942
- ISSN
- 1462-2203 (ISSN-L)
- 1469-994X
- OpenAlex
- W2141151785
- Cited by
- 58
- References
- 17
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? https://app.cochat.ai/papers/10.1080/14622200310001615295
- The paper
- Murphy, M., Johnstone, E., Griffiths, S.-E., Walton, R., David, S., Niaura, R., Papandonatos, G., Shadel, W., Burkholder, G., Britt, D., Day, A., Stumpff, J., & Hutchison, K. (2003). Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? Nicotine & Tobacco Research. https://doi.org/10.1080/14622200310001615295
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.